Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethyl Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL3559241 | 1.00 | — | — | |
| Ethyl Acetate SCHEMBL28314227 | 1.00 | ALDH1A1 (0.93) | — | |
| Ethyl Acetate SCHEMBL28097325 | 1.00 | ALDH1A1 (0.93) | — | |
| Ethyl Acetate SCHEMBL9599802 | 1.00 | ALDH1A1 (0.93) | — | |
| Ethyl Acetate SCHEMBL25250531 | 0.97 | — | — | |
| Ethyl Acetate SCHEMBL10647617 | 0.97 | — | — | |
| Ethyl Acetate SCHEMBL4344269 | 0.97 | — | — | |
| Ethyl Acetate SCHEMBL4306480 | 0.97 | — | — | |
| Ethyl Acetate SCHEMBL3863175 | 0.97 | — | — | |
| Ethyl Acetate SCHEMBL10473461 | 0.97 | ALDH1A1 (0.88) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14027 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071449-A | Substituted biphenyl compounds and application thereof in synthesis of cola pyrroside | 北京凯因格领生物技术有限公司 | 2026-05-22 | — | — | CN | claimed |
| CN-122010821-A | Adaglazecloth Synthesis method of intermediate | 上海博氏医药科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12440492-B2 | Pharmaceutical compositions comprising AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2025-10-14 | — | — | US | claimed |
| EP-4613333-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-10 | — | — | EP | claimed |
| CN-120157595-A | Organic gel with nano-helix morphology and preparation method thereof | 大连理工大学宁波研究院 | 2025-06-17 | — | — | CN | claimed |
| CN-120131636-A | Twin medicine and composition and application thereof | 江苏海洋大学 | 2025-06-13 | — | — | CN | claimed |
| CN-120118096-A | Synthesis and purification method of levofloxacin hydrochloride | 江西大地制药有限责任公司 | 2025-06-10 | — | — | CN | claimed |
| CN-116425642-B | Preparation method of 2-methoxy-4-fluoro-5-aminophenol | 浙江科聚生物医药有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-118851927-B | Preparation process of dimethylcaline hydrochloride | 海南三帝制药有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-115960346-B | Amphiphilic polymer with retinol derivative as hydrophobic chain | 中国药科大学 | 2025-05-27 | — | — | CN | claimed |
| CN-1465586-A | Cyclic Wushengtai and preparation method thereof | 瑞安大药厂股份有限公司 | 2004-01-07 | — | — | CN | claimed |
| US-20030191278-A1 | Cyclic pentapeptides and their preparation | PURZER PHARMACEUTICAL CO., LTD. (TW) | 2003-10-09 | — | — | US | claimed |
| US-20030069285-A1 | Novel solvate and crystalline forms of lercanidipine hydrochloride | RECORDATI IRELAND LIMITED | 2003-04-10 | — | — | US | claimed |
| CN-1077886-C | Amidino derivatives useful as nitric oxide synthase inhibitors | SEARLE & CO (US) | 2002-01-16 | — | — | CN | claimed |
| EP-1027609-A2 | METHOD FOR DETERMINATION OF DRUGS OF ABUSE IN BIOLOGICAL SAMPLES | Varian, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999022244-A2 | METHOD FOR DETERMINATION OF DRUGS OF ABUSE IN BIOLOGICAL SAMPLES | VARIAN, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| CN-1137268-A | Amidino derivatives useful as nitric oxide synthase inhibitors | SEARLE & CO (US) | 1996-12-04 | — | — | CN | claimed |
| EP-0640628-A2 | Crosslinked polyacrylic acids having low solvent residue, a process for the preparation therof and the use thereof as thickening agents | 3V SIGMA S.p.A (IT) | 1995-03-01 | — | — | EP | claimed |
| US-5342911-A | Solvent mixture containing methylene chloride and an ester | 3V INC. (US) | 1994-08-30 | — | — | US | claimed |
| EP-0390905-B1 | AMIDOFLUORINATED COMPOUNDS, METHOD FOR PRODUCING AND USING SAID COMPOUNDS | SZONYI, Istvan (FR) | 1993-08-11 | — | — | EP | claimed |